Management

Is deflection a good business tactic?

Wharton’s Maurice Schweitzer is the co-author of the first study to examine the costs and benefits of answering a question with a question.

From Knowledge at Wharton

How middle managers can help make a more equitable workplace

A new report from Wharton shows how companies can make a more diverse, equitable, and inclusive workplace with the help of middle managers, who ultimately shape the environment and daily experiences of employees.

From Knowledge at Wharton

How to bring your conscience to work

Wharton’s G. Richard Shell talks about how employees and managers can stand up for their values and create a more ethical workplace.

From Knowledge at Wharton



In the News


BBC

Boycotts aren’t the only way to hold companies accountable

Maurice Schweitzer of the Wharton School says that calls to boycott companies are complicated by the sister brands and different platforms of large corporations.

FULL STORY →



WHYY (Philadelphia)

Should you be friends with your coworkers?, update from the polls, jazz trumpet player Terell Stafford

Nancy Rothbard of the Wharton School explains how to manage the upsides and downsides of workplace friendships.

FULL STORY →



The New Yorker

How to die in good health

PIK Professor Ezekiel Emanuel says that incessantly preparing for old age mistakes a long life for a worthwhile one.

FULL STORY →



WHYY (Philadelphia)

Bridging Blocks has Philadelphians focused on dispelling myths around immigration

Exequiel Hernandez of the Wharton School says that immigrants are net positive contributors to everything that makes a community prosperous.

FULL STORY →



Yahoo! Finance

AI will change work, for better and worse

Sonny Tambe of the Wharton School says that AI is a useful tool for most people, not an existential threat.

FULL STORY →



Associated Press

Many cancer drugs remain unproven five years after accelerated approval, a study finds

PIK Professor Ezekiel Emanuel says that there should be definitive benefits to cancer drugs five years after their initial accelerated approval.

FULL STORY →